Back to top
more

Quest Diagnostics (DGX)

(Delayed Data from NYSE)

$153.95 USD

153.95
499,931

-1.30 (-0.84%)

Updated Oct 1, 2024 04:00 PM ET

After-Market: $153.88 -0.07 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 251)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

AtriCure's Shares Likely to Benefit From New AtriClip Device Sales

ATRC announces the treatment of the first patient using the AtriClip FLEX-Mini device.

Indrajit Bandyopadhyay headshot

Aveanna Stock Rallies 110% in 3 Months: Is It Still Worth Buying?

AVAH stock has the potential to continue its uptrend on the back of a better payer rate environment and its focus on high-paying customers.

Is HealthEquity Stock a Hold Now Amid Strong Top-Line Growth?

HQY's sustained strength in HSAs raises optimism about the stock.

GE Healthcare to Unveil AI-Driven Cardiac Diagnostics at ESC 2024

GEHC launches AI-enhanced ultrasound and ECG-less Cardiac CT technologies, offering rapid, accurate cardiac diagnostics at the point of care.

Quest Diagnostics Expands in North America With New Acquisition

DGX acquires 100% of LifeLabs from OMERS, at approximately $1 billion. It will help LifeLabs to improve healthcare for Canadians.

MCK Stock's Uptrend Likely to Continue After Core Ventures Acquisition

McKesson's agreement to acquire a controlling interest will likely bring advanced treatments and improved care experiences to patients.

Teleflex's (TFX) Titan SGS Stapler Showcases Positive Outcomes

Teleflex (TFX) publishes an analysis of clinical data showcasing the Titan SGS Stapler's enhanced clinical outcomes and significant efficiency benefits.

Inari Medical (NARI) Issues Notice Post ClotTriever XL Recall

Inari Medical (NARI) issues urgent updates to ClotTriever XL Catheter instructions following the FDA's recall after reports of serious injuries and deaths.

Ekso Bionics (EKSO) Addressable Market to Grow on CMS Update

The CMS reimbursement is pivotal for Ekso Bionics (EKSO), as it opens up substantial opportunities in a market where cost has often been a barrier to access

Quest Diagnostics' (DGX) New Deal Aids Diagnostic Access in Ohio

Quest Diagnostics (DGX) signs an agreement to acquire select assets of University Hospitals' outreach laboratory services business.

SI-BONE (SIBN) Receives FDA Nod for Its TNT Implant System

SI-BONE (SIBN) receives FDA 510(k) clearance for its iFuse TORQ TNT implant system, followed by a Breakthrough Device Designation award by the FDA.

AtriCure's (ATRC) AtriClip Receives Expanded CE-Mark Indication

AtriCure (ATRC) announces the receipt of an expanded CE-Mark indication for its AtriClip devices for reducing strokes in patients with Afib.

Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY

Microbot Medical (MBOT) signs a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures using LIBERTY.

INSPIRA (IINN) CART Gets FDA Listing, to Enhance Healthcare

Inspira (IINN) announces FDA listing of its INSPIRA CART, designed for use with the ART100 system, enhancing healthcare delivery during cardiopulmonary bypass.

Henry Schein (HSIC) Hurt by Macroeconomic Woes, Cyber Attacks

With sustained macroeconomic pressure, Henry Schein (HSIC) struggles to keep in check its cost of revenues and operating expenses.

Chemed (CHE) Up 5.7% Since Last Earnings Report: Can It Continue?

Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Stryker's (SYK) Inks Deal to Aid Its Pain Management Portfolio

Stryker (SYK) is set to acquire Vertos Medical to expand its interventional pain management portfolio.

Abbott (ABT) Gets FDA Approval for Aspirin-Free HeartMate 3 Regimen

Abbott's (ABT) labeling update, exclusively for patients with a HeartMate 3 heart pump, secures the FDA's approval.

Cencora (COR) Gains 16.6% YTD: What's Driving the Stock?

Cencora (COR) gaining traction from the robust U.S. Healthcare Solutions segment raises optimism about the stock.

PROCEPT BioRobotics' (PRCT) HYDROS System Gets FDA Clearance

PROCEPT BioRobotics (PRCT) announces the FDA 510(k) clearance of its HYDROS Robotic System for providing better BPH treatment.

Quest Diagnostics (DGX) Up 6.3% Since Last Earnings Report: Can It Continue?

Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Cardinal Health (CAH) to Open New Distribution Center in Ohio

Cardinal Health's (CAH) new center is set to integrate cutting-edge technology and automation, enhancing efficiency, storage capacity and quality of service.

Exact Sciences (EXAS) Rides on Cologuard Sales, New Launches

Exact Sciences (EXAS) identifies more than 100 opportunities with payers and health systems to address the care gaps with Cologuard through screening programs.

Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?

Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

PROCEPT (PRCT) Grows in Urology With FDA Clearance for HYDROS

PROCEPT's (PRCT) HYDROS Robotic System leverages AI-driven technology, specifically FirstAssist AI, to optimize treatment planning.